title: [Sensitivity surveillance of Streptococcus pneumoniae isolates for several antibiotics in Gifu prefecture (2004)].
abstract: We analyzed Streptococcus pneumoniae isolates in Gifu prefecture between November 2004 and December 2004. We analyzed isolates of 160 strains from 8 medical facilities to determine antibiotic susceptibility, genotype of penicillin-binding protein (PBP) genes and macrolide resistant genes, and the serotypes of penicillin-resistant S. pneumoniae (PRSP). When referred to the classification in CLSI (formerly NCCLS), the overall incidence of penicillin-susceptible (PSSP), penicillin-intermediate (PISP) and penicillin-resistant (PRSP) were 48 (30.0%), 81 (50.6%) and 31 (19.4%) strains, respectively, and the susceptibility distribution to benzylpenicillin showed triplet peaks. The incidence of PISP and PRSP was higher in the material of throat and nasal cavity, and area of Chuno and Gifu district. The sum of the incidence of PISP and PRSP was slightly higher in inpatient-derived stains than outpatient-derived strains. The incidence that didn't possess mutations in PBP genes and macrolide-resistant genes was 6 (3.75%) and the others 154 strain (96.25%) had abnormal PBP genes or macrolide-resistant genes. The 90% of pneumococcal serotypes of PRSP 31 strains were serotype 6 (14 strains, 45.2%), 19 (7 strains, 22.6%) and 23 (7 strains, 22.6%). The MIC90 of each antibiotics was as follows; 0.1 microg/mL for panipenem, 0.2 microg/mL for imipenem and tosufloxacin, 0.39 microg/mL for meropenem and gatifloxacin, 0.78 microg/mL for amoxicillin, cefteram and cefditoren, 1.56 microg/mL for piperacillin, cefcapene and levofloxacin, 3.13 microg/mL for flomoxef, 6.25 microg/mL for cefdinir and cefotiam, 12.5 microg/mL for norfloxacin and minocycline, 25 microg/mL for cefixime, and 100 microg/mL for clarithromycin.
authors.affiliation: Research Laboratories of Toyama Chemical Co., Ltd.
authors.forename: Junichi
authors.initials: J
authors.lastname: Mitsuyama
authors.forename: Kazukiyo
authors.initials: K
authors.lastname: Yamaoka
authors.forename: Yuko
authors.initials: Y
authors.lastname: Asano
authors.forename: Haruki
authors.initials: H
authors.lastname: Sawamura
authors.forename: Hiroyuki
authors.initials: H
authors.lastname: Suematsu
authors.forename: Mayumi
authors.initials: M
authors.lastname: Terachi
authors.forename: Hikonori
authors.initials: H
authors.lastname: Hashido
authors.forename: Yoko
authors.initials: Y
authors.lastname: Matsukawa
authors.forename: Shigenori
authors.initials: S
authors.lastname: Matsubara
authors.forename: Takanori
authors.initials: T
authors.lastname: Miyabe
authors.forename: Hiroshige
authors.initials: H
authors.lastname: Mikamo
authors.forename: Kunitomo
authors.initials: K
authors.lastname: Watanabe
mesh_terms: D000900:Anti-Bacterial Agents / Q000494:pharmacology*; D024881:Drug Resistance, Bacterial / Q000235:genetics; D005838:Genotype; D006801:Humans; D007564:Japan; D009154:Mutation; D009296:Nasal Cavity / Q000382:microbiology; D010400:Penicillin G / Q000494:pharmacology; D010403:Penicillin Resistance; D046915:Penicillin-Binding Proteins / Q000235:genetics; D010614:Pharynx / Q000382:microbiology; D012703:Serotyping; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics / Q000276:immunology
chemical_list: D000900:Anti-Bacterial Agents; D046915:Penicillin-Binding Proteins; D010400:Penicillin G